DAILY NEWS / TRENDING NEWS

 On September 22, 2025, President Donald Trump made headlines with a sweeping announcement about autism spectrum disorder (ASD), calling for new research, treatment access, and public health warnings. Speaking from the White House, Trump linked prenatal Tylenol use to rising autism rates and unveiled a federal initiative aimed at expanding autism care and scientific investigation.

During the press briefing, Trump stated:

“Effective immediately, the FDA will notify physicians that acetaminophen use during pregnancy may be associated with a very increased risk of autism. Ideally, a woman won’t take Tylenol.”

He described the announcement as “one of the biggest medical revelations in the history of our country,” and emphasized that his administration would “not let it happen anymore.” Trump’s remarks were delivered alongside Health Secretary Robert F. Kennedy Jr. and Dr. Mehmet Oz, both of whom have advocated for deeper investigation into environmental and pharmaceutical factors linked to autism.

The Trump administration cited recent studies from institutions like Harvard University and Mount Sinai Hospital, which examined possible associations between acetaminophen exposure during pregnancy and neurodevelopmental outcomes. However, leading health organizations—including the CDC, American Academy of Pediatrics, and Autism Science Foundation—have responded with caution.

The FDA issued a statement clarifying that while some studies suggest a potential link, no causal relationship has been proven, and further research is needed. Medical experts warn that discouraging Tylenol use could lead to untreated fever or pain during pregnancy, which may pose greater risks to fetal development.

In addition to the Tylenol warning, Trump announced that the FDA has approved a label update for leucovorin, a folinic acid drug previously used off-label to treat cerebral folate deficiency. The updated label now includes treatment for speech-related symptoms in children with autism.

Key points from the initiative:

• Medicaid coverage for leucovorin will expand nationwide

• NIH trials will study its long-term safety and effectiveness

• The drug is not a cure, but may help improve speech and social behavior in select cases

Autism diagnoses have increased significantly over the past two decades. According to the CDC, 1 in 31 children born in 2022 were diagnosed with ASD, compared to 1 in 150 in 2000. Trump’s administration attributes part of this rise to environmental and pharmaceutical exposures, though most scientists cite expanded diagnostic criteria and greater awareness.

To address the growing concern, Trump announced a multi-agency autism research initiative, which will explore more than 30 potential causes, including:

• Pharmaceutical exposure during pregnancy

• Genetic predisposition

• Environmental toxins

• Vaccine scheduling (though Trump clarified this is a personal belief, not official policy)

The announcement has sparked mixed reactions. Kenvue, the manufacturer of Tylenol, issued a strong rebuttal:

“Independent, sound science clearly shows that acetaminophen does not cause autism. We are deeply concerned with the health risk this poses for expecting mothers.”

Meanwhile, autism advocacy groups have expressed cautious optimism about increased funding and treatment access, while urging the administration to avoid spreading fear or misinformation.

President Trump’s statement about autism and Tylenol has reignited national debate over prenatal health, pharmaceutical safety, and autism research. While the administration promises bold reforms and expanded care, medical experts emphasize the need for evidence-based policy, scientific rigor, and clear communication.

As new studies unfold and treatments like leucovorin gain traction, families affected by autism are watching closely—hoping for clarity, compassion, and credible solutions.

For ongoing updates, visit HHS.gov, FDA.gov, and CDC Autism Data.

 In a bold and controversial move, President Donald Trump announced on September 22, 2025, that his administration has identified a potential link between Tylenol use during pregnancy and increased risk of autism spectrum disorder (ASD) in children. The announcement, made during a White House press event alongside Health Secretary Robert F. Kennedy Jr. and Dr. Mehmet Oz, has ignited fierce debate among medical experts, pharmaceutical companies, and public health advocates.

What Trump Said About Tylenol and Autism

Speaking from the Roosevelt Room, Trump declared:

“Effective immediately, the FDA will notify physicians that acetaminophen use during pregnancy may be associated with a very increased risk of autism. Ideally, a woman won’t take Tylenol.”

He described the announcement as “one of the biggest medical revelations in the history of our country,” and emphasized that his administration “won’t let it happen anymore.” Trump also hinted at broader reforms in childhood vaccination schedules, suggesting that vaccines should be administered in “smaller doses over a longer period,” though he acknowledged these were personal views not backed by medical consensus.

The Trump administration cited recent reviews, including studies from Harvard University and Mount Sinai Hospital, that examined a possible association between acetaminophen exposure in early pregnancy and neurodevelopmental outcomes. However, leading health organizations—including the American College of Obstetricians and Gynecologists, CDC, and Autism Science Foundation—have pushed back, stating that no causal link has been established.

The FDA, while issuing a cautionary advisory, clarified:

“An association between acetaminophen and autism has been described in some studies, but a causal relationship has not been proven. This remains an ongoing area of scientific debate.”

In addition to the Tylenol warning, Trump and RFK Jr. announced that the FDA has approved a label update for leucovorin, a folinic acid drug previously used off-label to treat cerebral folate deficiency. The updated label now includes treatment for speech-related symptoms in children with autism.

State Medicaid programs will begin covering leucovorin for eligible children, and the NIH will launch confirmatory trials to study its long-term safety and efficacy. Officials emphasized that leucovorin is not a cure, but may offer speech and social improvements for a subset of children with ASD.

The announcement has drawn sharp criticism from medical experts and pharmaceutical companies. Kenvue, the parent company of Tylenol, issued a statement saying:

“Independent, sound science clearly shows that acetaminophen does not cause autism. We strongly disagree with any suggestion otherwise and are deeply concerned with the health risk this poses for expecting mothers.”

Doctors warn that discouraging Tylenol use could lead pregnant women to suffer through untreated fevers and pain, which may pose greater risks to both mother and baby than acetaminophen itself.

Autism diagnoses have surged in the U.S. over the past two decades. According to the CDC, 1 in 31 children born in 2022 were diagnosed with ASD, compared to 1 in 150 in 2000. RFK Jr. has long argued that environmental toxins—including pharmaceuticals—may be contributing to this rise, though most scientists attribute the increase to expanded diagnostic criteria and greater awareness.

The administration has launched a multi-agency research initiative to investigate over 30 hypotheses related to autism’s causes, including genetic, environmental, and pharmaceutical factors. However, experts caution that definitive answers may take years to emerge.

President Trump’s announcement linking Tylenol to autism has reignited national debate over prenatal health, pharmaceutical safety, and autism research. While the administration promises “historic progress,” medical experts urge caution, emphasizing the need for rigorous science and balanced public messaging.

As new studies unfold and treatments like leucovorin enter the mainstream, families affected by autism are watching closely—hoping for clarity, support, and solutions rooted in evidence.